Company Information

  

Address: 300 THIRD STREET  
City: CAMBRIDGE 
State: MA 
Zip Code: 02142 
Telephone: (617) 551-8200 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a global biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. We are harnessing the RNAi pathway to develop a potential new class of innovative medicines, known as RNAi therapeutics. RNAi therapeutics are comprised of small interfering RNA, or siRNA, and function upstream of today's medicines by potently silencing messenger RNA, or mRNA, that encode for disease-causing proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. Our research and development strategy is to target genetically validated liver-expressed genes that have been implicated in the cause or pathway of human disease.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-5.58NAN/E
12/2017-5.42NAN/E
09/2017-5.24NAN/E
06/2017-5.12NAN/E
03/2017-4.83NAN/E
12/2016-4.79NAN/E
09/2016-4.55NAN/E
06/2016-4.24NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.12Total Liab/Total Assets0.11
Net Inc/Total Assets-0.25Total Liab/Inv Cap0.12
Net Inc/Inv Cap-0.27Total Liab/Comm Equity0.06
Pretax Inc/Net Sales-5.46Interest Coverage RatioNA
Net Inc/Net Sales-5.46Curr Debt/EquityNA
Cash Flow/Net Sales-4.26LTD/Equity0.02
SG&A/NetSales2.22Total Debt/Equity0.02
Asset Utilization   Liquidity  
Net Receivables Turnover3.14Quick Ratio12.23
Inventory TurnoverNACurrent Ratio12.23
Inventory Day SalesNANet Rec/Curr Assets0.02
Net Sales/Work Cap0.06Inv/Curr AssetsNA
Net Sales/PP&E0.49  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 21.90 37.92 17.10 15.93
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 72.45 67.46 47.64 45.78
Operating Income -147.41 -147.30 -125.80 -120.47
Interest Exp NA NA NA NA
Pretax Income -141.28 -142.23 -122.94 -118.42
Other Income 6.13 5.08 2.86 2.05
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -141.21 -142.23 -122.94 -118.42

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 1,567.86 1,690.62 948.29 923.27
Receivables - Total 50.77 34.00 14.64 15.41
Inventories - Total NA NA NA NA
Total Current Assets 1,685.30 1,764.74 993.37 960.71
Net Property, Plant & Equipment 201.98 181.90 161.90 147.53
Total Assets 1,923.14 1,994.73 1,358.28 1,434.28
Liabilities        
Accounts Payable 77.03 100.56 60.50 66.99
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 115.38 144.25 101.05 108.73
Long-Term Debt 30.00 30.00 150.00 150.00
Total Liabilities 168.33 228.30 299.45 311.32
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 1.01 1.00 0.92 0.92
Retained Earnings -2,220.69 -2,147.69 -2,005.46 -1,882.52
Treasury Stock NA NA NA NA
Total Stockholders' Equity 1,754.81 1,766.43 1,058.84 1,122.97
Total Liabilities and Stockholders' Equity 1,923.14 1,994.73 1,358.28 1,434.28

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -155.66 -103.04 -98.36 -81.05
Net Cash Provided by Investing Activities -134.81 -160.59 -137.18 -67.67
Net Cash Provided by Financing Activities 41.52 706.95 28.92 386.31

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201347.17-89.22-1.45
12/201450.56-360.40-4.85
12/201541.10-290.07-3.45
12/201647.16-410.11-4.79
12/201789.91-490.87-5.42
Growth Rates17.50----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1832793,26092.78




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.